ABCA1 and cancer: Efforts to artificially increase the cholesterol-removing pre-β/discoidal HDL fraction to drive ABCA1-mediated net cholesterol depletion from cancer cells might therefore provide a molecular axis that offers therapeutic potential for the treatment of PDAC.